Abiomed reports preliminary Q3 2019 revenue of $201M

|By:, SA News Editor

Abiomed (ABMD -1.5%) reports preliminary Q3 2019 revenue of ~$200.6M, an increase of 30% over Q3 2018 revenue of $154M.

U.S. Impella product revenue grew 27% to ~$165.7M.

Outside the U.S., Impella product revenue totaled $27.5M.

The company is raising its FY 2019 revenue guidance to ~$780M, from a range of $765M to $770M.

The company will release full Q3 2019 results via conference call at 8:00 a.m. EST on January 31.

#JPM19

Subscribe for full text news in your inbox